NCT06820762View on ClinicalTrials.gov

Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
SCLC
Interventions
DRUG

irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity

"Drug: ivonescimab 20mg/kg, IV, D1, Q3W~Other Names:~AK112 Drug: irinotecan liposome(II) 70mg/m\^2, IV, D1, Q3W"

Trial Locations (2)

110022

Shengjing Hospital of China Medical University, Shenyang

116027

The Second Affiliated Hospital of Dalian Medical University, Dalian

All Listed Sponsors
collaborator

Shengjing Hospital

OTHER

lead

The Second Affiliated Hospital of Dalian Medical University

OTHER